Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia
about
Current and emergent treatments for symptoms and neurocognitive impairment in schizophrenia.The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychoticsInvega Trinza: The First Four-Times-a-Year, Long-Acting Injectable Antipsychotic Agent.Physician and patient benefit-risk preferences from two randomized long-acting injectable antipsychotic trials.The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.Paliperidone Palmitate Intramuscular 3-Monthly Formulation: A Review in Schizophrenia.Medication adherence in patients with psychotic disorders: an observational survey involving patients before they switch to long-acting injectable risperidone.Highlights from the Conference on Retroviruses and Opportunistic Infections 2016: 22-25 February 2016, Boston, Massachusetts, USA.Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study.Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study.Schizophrenia therapy options increasing.Economic evaluation of paliperidone palmitate once monthly for treating chronic schizophrenia patients in the United Arab Emirates.Clinical improvement, relapse and treatment adherence with paliperidone palmitate 1-month formulation: 1-year treatment in a naturalistic outpatient setting.An open-treatment six-week study of the clinical effectiveness of Paliperidone Palmitate in schizophrenia: data from acute units in Spain (SHADOW study).The Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations, Outcomes (REACH-OUT) study: real-world clinical practice in schizophrenia.Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.The effects of switching from oral to LAI antipsychotic treatment on subjective experience of schizophrenic and schizoaffective patients: Preliminary results.A New Level A Type IVIVC for the Rational Design of Clinical Trials Toward Regulatory Approval of Generic Polymeric Long-Acting Injectables.Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects.Patterns of Prescription of Psychotropic Medications and Their Adherence among Patients with Schizophrenia in Two Psychiatric Hospitals in Accra, Ghana: A Cross-Sectional Survey.A systematic literature review of the clinical and health economic burden of schizophrenia in privately insured patients in the United States.Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics - expert consensus survey part 1.Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence.
P2860
Q30382281-724172A2-1BD1-4C3A-8532-7ED4753300B0Q34418847-3B174966-611C-4272-BD71-F04860075DCCQ36467615-8CCE8B7D-7485-43DC-984A-8C59ACE50DEAQ36738169-DFAFEC09-C76C-4CFC-9C8C-F519396A3FB9Q37376779-03E21AF5-EFA2-4FAD-900F-4D340D5D4DA4Q38570636-BB715580-BBA5-4470-A38D-949690EE4199Q38971631-A6864D3A-6C60-4EE3-81B6-F51D2CA56E27Q40512185-7DE949E0-47ED-4861-877C-A682E3D1490FQ40591692-C2FEF2CD-CF2D-4D08-9C88-156DE1BA47B1Q40765718-E238BE3E-F1FD-4DCF-8515-7FCCC24052FCQ41283940-ED0275D5-6D16-44A9-978B-AB92ABF71CEDQ42870732-8FD34801-310E-46F1-9FF6-2AC92F6963C3Q47225222-99A68C78-8BD2-45F9-B6A0-8DCF9D80F628Q47247292-7480AF87-A78E-43E9-8F04-648EBD8DB485Q47434414-AA6F7804-B5CF-45D6-9D15-C74800295C65Q47551032-829E0B12-36B7-4F2D-9BBD-A250AADBDB38Q47998008-B088F045-BAB1-49FB-A0A8-0F9DE67098F0Q48059462-652415E3-ED08-4B5C-B835-D02A79058FA4Q48184180-2BF76AB8-35E4-4546-9A6A-248B3AA85939Q49787745-F60E28C6-1BAF-44B6-BB84-4D6135A54A90Q53434932-CC0C0C68-09B5-46D4-828F-BAFECA69CB2EQ55161186-64E48A73-B251-4221-9B3F-FB1074A3D745Q55364906-73E21509-7E28-402D-88A6-332E696AFF0DQ55556616-55DC9807-D248-4FB4-BB21-408BED90B42B
P2860
Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Impact of long-acting injectab ...... omic outcomes of schizophrenia
@ast
Impact of long-acting injectab ...... omic outcomes of schizophrenia
@en
Impact of long-acting injectab ...... omic outcomes of schizophrenia
@nl
type
label
Impact of long-acting injectab ...... omic outcomes of schizophrenia
@ast
Impact of long-acting injectab ...... omic outcomes of schizophrenia
@en
Impact of long-acting injectab ...... omic outcomes of schizophrenia
@nl
prefLabel
Impact of long-acting injectab ...... omic outcomes of schizophrenia
@ast
Impact of long-acting injectab ...... omic outcomes of schizophrenia
@en
Impact of long-acting injectab ...... omic outcomes of schizophrenia
@nl
P2093
P2860
P3181
P356
P1476
Impact of long-acting injectab ...... omic outcomes of schizophrenia
@en
P2093
Gabriel Kaplan
Jacqueline Zummo
Julio Casoy
P2860
P304
P3181
P356
10.2147/PPA.S53795
P407
P577
2013-01-01T00:00:00Z